CN102675425A - Functional mycobacterium tuberculosis antigen polypeptide and application thereof - Google Patents
Functional mycobacterium tuberculosis antigen polypeptide and application thereof Download PDFInfo
- Publication number
- CN102675425A CN102675425A CN2012101148613A CN201210114861A CN102675425A CN 102675425 A CN102675425 A CN 102675425A CN 2012101148613 A CN2012101148613 A CN 2012101148613A CN 201210114861 A CN201210114861 A CN 201210114861A CN 102675425 A CN102675425 A CN 102675425A
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- mouse
- application
- pep2
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 26
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 24
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 24
- 239000000427 antigen Substances 0.000 title abstract description 14
- 102000036639 antigens Human genes 0.000 title abstract description 14
- 108091007433 antigens Proteins 0.000 title abstract description 14
- 241000187479 Mycobacterium tuberculosis Species 0.000 title abstract description 11
- 210000004698 lymphocyte Anatomy 0.000 claims abstract description 19
- 201000008827 tuberculosis Diseases 0.000 claims abstract description 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 7
- 210000000952 spleen Anatomy 0.000 claims description 17
- 210000004027 cell Anatomy 0.000 claims description 13
- 208000015181 infectious disease Diseases 0.000 claims description 10
- 229960005486 vaccine Drugs 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 5
- 241000894006 Bacteria Species 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 230000008521 reorganization Effects 0.000 claims description 2
- 230000009261 transgenic effect Effects 0.000 claims description 2
- 239000013598 vector Substances 0.000 claims description 2
- 241000894007 species Species 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 abstract description 4
- 230000035755 proliferation Effects 0.000 abstract description 4
- 210000004989 spleen cell Anatomy 0.000 abstract description 2
- 230000003449 preventive effect Effects 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- 229940021747 therapeutic vaccine Drugs 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 34
- CQTGBCFGAAYOCY-ZCRNMIQFSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-amino-5-oxopentanoyl]amino]-4-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-3-methyl-1-oxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-4-oxobutanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@@H](NC(C)=O)C(C)C)C(C)C)[C@@H](C)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](C(C)C)C(N)=O CQTGBCFGAAYOCY-ZCRNMIQFSA-N 0.000 description 24
- 101100189913 Caenorhabditis elegans pept-1 gene Proteins 0.000 description 24
- 108010088535 Pep-1 peptide Proteins 0.000 description 19
- 239000000243 solution Substances 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 11
- 210000002751 lymph Anatomy 0.000 description 9
- 239000012980 RPMI-1640 medium Substances 0.000 description 7
- 235000015097 nutrients Nutrition 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 230000000527 lymphocytic effect Effects 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 102000005431 Molecular Chaperones Human genes 0.000 description 2
- 108010006519 Molecular Chaperones Proteins 0.000 description 2
- 241001646725 Mycobacterium tuberculosis H37Rv Species 0.000 description 2
- 108700035964 Mycobacterium tuberculosis HsaD Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000011217 control strategy Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000003859 hyphenated technique Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 101100507655 Canis lupus familiaris HSPA1 gene Proteins 0.000 description 1
- 241001232809 Chorista Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010013453 Disseminated tuberculosis Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 201000006836 Miliary Tuberculosis Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 208000036984 extensively drug-resistant tuberculosis Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000009671 multidrug-resistant tuberculosis Diseases 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 229960002109 tuberculosis vaccine Drugs 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
本发明公开了功能性结核分枝杆菌抗原多肽及其应用。本发明所提供的多肽，其氨基酸序列如序列表中序列2所示。该多肽可刺激H37Rv感染小鼠脾脏细胞和淋巴细胞显著增殖，并可以与感染小鼠血清发生抗原-抗体反应，说明此多肽具有抗原性，可用于开发新型结核病预防性和治疗性疫苗。The invention discloses functional Mycobacterium tuberculosis antigen polypeptide and application thereof. The amino acid sequence of the polypeptide provided by the present invention is shown in Sequence 2 in the sequence listing. The polypeptide can stimulate the significant proliferation of spleen cells and lymphocytes of H37Rv-infected mice, and can react with the serum of infected mice, indicating that the polypeptide has antigenicity and can be used to develop new preventive and therapeutic vaccines for tuberculosis.
Description
Technical field
The present invention relates to a kind of functional antigen of mycobacterium tuberculosis polypeptide and application thereof.
Background technology
Add up according to WHO; Nearly in the world 1/3 population infects has mycobacterium tuberculosis (M.tb); And along with increasing of resistant tuberculosis and white plaque and AIDS polyinfection patient; White plaque is the serious harm people ' s health, according to statistics in recent years in China's infectious disease incidence number and death toll phthisical rank occupy front two always.White plaque has been the transmissible disease of a kind of serious harm people ' s health and national economy, and China is the high state that bears lungy, and the formulation for white plaque prevention and control strategy just becomes the significant problem that concerns China's national economy so.Maximum surely belonging to " chemotherapy " used in treatment lungy at present; The treatment of chemicals has obvious effects to white plaque; But along with " anti-multiple medicines tuberculosis " (MDR-TB) with " serious resistance tuberculosis " (XDR-TB) rising of sickness rate, chemotherapy has shown limitation.So, the new method of preventing and treating just becomes problem demanding prompt solution.All the time, utilize immunological method to seek new effective prevention and treat focus and the emphasis that means lungy all are this area researches.Utilization vaccine prevention and treatment white plaque are one of white plaque prevention and control strategies the most effectively, but present stage progress slow.At present, uniquely can be used for preventing that vaccine lungy---BCG-CWS (BCG) only has the certain protection effect to children's disseminated tuberculosis, but it is generally acknowledged adult's tuberculosis protection effect more weak.Though some novel tuberculosis disease vaccines are developed in succession, still are in the exploratory stage mostly, effect is not satisfactory.Wherein major reason is unclear except white plaque immunoprotection mechanism, causes that in different infection period the effective antigen of mycobacterium tuberculosis of immunoprotection reaction is still indeterminate exactly, and this just becomes the obstacle of vaccine design and immunization strategy formulation.Antigen is related to the success or failure of vaccine, filter out so with fall ill closely-related functional antigen and understand its immunne response mechanism better just can be for the vaccine of developing different clinical demands, formulate immunization strategy more practical applications selections are provided.
There are some researches show in the tumor research field; Utilization can cause the specific immune response to tumour antigen after containing Hsp70, Gp96 proteic vaccine immune mouses such as (molecular chaperone proteins of tumor cells expression), infers that Chaperones Molecular carries the tsa peptide; In the infection research field, the Gp96 albumen that has research from the hepatitis B lesion tissue, to extract has one section HBV specific antigens.For the pulmonary tuberculosis research field, also there not be at present directly the relevant report of in lung tissue, screening negre antigen.
Summary of the invention
An object of the present invention is to provide a kind of polypeptide that promotes the lymphopoiesis function that has.
Polypeptide provided by the present invention, name is called Pep2, and its aminoacid sequence is shown in sequence in the sequence table 2.
Wherein, the sequence in the sequence table 2 is made up of 16 amino-acid residues.
The gene of coding Pep2 and contain this expression of gene box, recombinant vectors, transgenic cell line and reorganization bacterium and also belong to protection scope of the present invention.
Pep2 is that contriver of the present invention integrates the liquid phase mass spectrometric hyphenated technique with the Rotofor technology, the antigen of mycobacterium tuberculosis polypeptide that directly filters out from patient's diseased lung tissue.Experiment showed, Pep2 can differential stimulus H37Rv infecting mouse spleen lymphocyte and lymph node lymphocyte significantly breed, can be used to prepare lymphopoiesis agent and development tuberculosis vaccine.
Description of drawings
Fig. 1 is that Pep1 and Pep2 stimulate mouse spleen and LNC proliferation experiment result.
Top right plot is the mouse spleen cell proliferation experiment.
Bottom-right graph is a mouse lymph nodal cell proliferation experiment.
Embodiment
Following embodiment is convenient to understand better the present invention, but does not limit the present invention.Experimental technique among the following embodiment like no specified otherwise, is ordinary method.
Used material, reagent etc. like no specified otherwise, all can obtain from commercial sources among the following embodiment.
The functional antigen of mycobacterium tuberculosis polypeptide that present embodiment adopts is Pep1 (fadB5-1) and Pep2 (fadB5-2), and the aminoacid sequence of Pep1 is shown in sequence in the sequence table 1; The aminoacid sequence of Pep2 is shown in sequence in the sequence table 2.
1, the preparation of Pep1 and Pep2
Pep1 and Pep2 adopt solid-phase polypeptide synthesis method (Fmoc method) synthetic to the aminoterminal direction by carboxyl terminal.Wherein, the resin that is adopted is that substitution value is 0.5 2-CL-Trt.The synthetic polypeptide adopts performance liquid chromatography to carry out purifying, and to obtain purity be 98% Pep1 and Pep2.The Pep1 and the Pep2 of purifying identify that through mass spectrum the aminoacid sequence of Pep1 is shown in sequence in the sequence table 1; The aminoacid sequence of Pep2 is shown in sequence in the sequence table 2.
2, stimulate mouse spleen and LNC proliferation experiment
Experiment flow is as shown in Figure 1, may further comprise the steps:
2.1 mycobacterium tuberculosis H37Rv infecting mouse Preparation of model
Mycobacterium tuberculosis H37Rv (mycobacterium tuberculosis experiment strain, ATCC, 25618) thaws the back at one week of 7H9 liquid nutrient medium recovery back tracer liquid substratum OD value, OD when bacterial growth is in increased logarithmic phase
580=0.5-0.8 (10.D=10
8CFU), be prepared into 5 * 10 with aseptic 0.9% saline water (containing 0.05%Tween-80) dilution bacterium thalline
5The inoculation liquid of CFU/mL.Every mouse (C57Black/B6 is available from Institute of Experimental Animals, Chinese Academy of Medical Sciences) tail vein injection bacterium 1 * 10
5CFU.Mouse infection H37Rv puts to death 8 week back, and the chorista cell experimentizes.
2.2 stimulate mouse spleen and LNC proliferation experiment
Aseptic separating spleen in abdominal cavity and thoracic cavity and lymphoglandula are cut off with eye scissors in mice sacrificed (healthy C57Black/B6 control mice of the same age and the C57Black/B6 mouse that infects H37Rv) 75% alcohol immersion sterilization back; Be immersed in the serum-free RPMI-1640 substratum of 10ml precooling; Take out the piston tissue abrasion of tissue with syringe; Nylon net filter falls fatty tissue and reticular tissue is prepared into unicellular homogenate, and this operation is accomplished at low temperatures.4 ℃ of 1500rpm of single cell suspension, 5min is centrifugal, abandons supernatant, recentrifuge behind aseptic 1 * PBS re-suspended cell.Add the aseptic 1 * PBS termination reaction that adds the 10ml precooling after the erythrocyte cracked liquid splitting erythrocyte of 500 μ L volumes, recentrifuge obtains mouse spleen lymphocyte and lymph node lymphocyte.Add the RPMI-1640 nutrient solution re-suspended cell that 2mL contains 10%FBS after abandoning supernatant, carry out cell counting, simultaneously the survival rate of observation of cell with trypan blue dyestuff pair cell.Establish following four experimental group and substratum background control group altogether: healthy C57Black/B6 mouse spleen lymphocyte group; Healthy C57Black/B6 mouse lymph knot lymphocyte group; H37Rv infects C57Black/B6 mouse spleen lymphocyte group, and H37Rv infects C57Black/B6 mouse lymph knot lymphocyte group.All establish following four processing for preceding four groups every group: adding mouse-anti people CD3CD28 antibody to final concentration in the reaction system is 1ug/ml, is 10ug/ml with RPMI-1640 nutrient solution to the final concentration of Pep1 and Pep2 adding 10%FBS respectively in the reaction system.Simultaneously, the cell of RPMI-1640 nutrient solution that only contains 10%FBS in the reaction system is as negative control.
RPMI-1640 nutrient solution adjustment cell concn to 1 * 10 that contain 10%FBS with no antibody and polypeptide
6Cell/ml, 4 parts of every group of cell suspension each minutes add in flat 96 orifice plates in above-mentioned four experimental group, and every porocyte adds up to 2 * 10
5Individual.A copy of it adds 10 μ L mouse-anti people CD3CD28 antibody-solutions (mouse anti-human CD3:BD, Cat.No.555336; Mouse ant i-human CD28:BD; Cat.No.555725)) to mouse-anti people CD3CD28 antibody final concentration be 1 μ g/ml (positive control in the table 1); A adding 10 μ L Pep1 solution to Pep1 final concentrations are 10ug/ml (Pep1 in the table 1); A adding 10 μ L Pep2 solution to Pep2 final concentrations are 10ug/ml (Pep2 in the table 1), a no antibody of 10 μ L and the RPMI-1640 nutrient solution that contains 10%FBS (negative control in the table 1) of polypeptide of adding.Each of above-mentioned four experimental group handled and respectively established 3 multiple holes.37 ℃ of 5%CO
2Incubation 72 hours; In the every hole of culture plate, add 10 μ L CCK-8 (Cell Counting Kit-8) solution, 37 ℃ of 5%CO
2Incubation 4 hours; Be determined at the absorbancy at 450nm place with ELIASA.Calculate SI Stimulation Index=(stimulating hole OD value-substratum background OD value)/(not stimulating hole OD value-substratum background OD value).Wherein, stimulate hole OD value to be meant and add the OD value that mouse-anti people CD3CD28 antibody, Pep1 or Pep2 irritation cell read; Do not stimulate hole OD value to be meant the OD value that the RPMI-1640 nutrient solution cell that contains 10%FBS of no antibody of adding and polypeptide reads.
Three repetitions are established in experiment; The result is as shown in table 1; Mouse-anti people CD3CD28 antibody is 1.21 to the SI of healthy C57Black/B6 mouse spleen lymphocyte, and mouse-anti people CD3CD28 antibody is 6.43 to the SI that H37Rv infects the C57Black/B6 mouse spleen lymphocyte; Pep1 is 0.94 to the SI of healthy C57Black/B6 mouse spleen lymphocyte, and the SI that 1 couple of H37Rv of Pep infects the C57Black/B6 mouse spleen lymphocyte is 2.71; Pep2 is 0.90 to the SI of healthy C57Black/B6 mouse spleen lymphocyte, and Pep2 is 3.24 to the SI that H37Rv infects the C57Black/B6 mouse spleen lymphocyte.It is 1.75 that mouse-anti people CD3CD28 antibody is tied lymphocytic SI to healthy C57Black/B6 mouse lymph, and it is 3.74 that mouse-anti people CD3CD28 antibody is tied lymphocytic SI to H37Rv infection C57Black/B6 mouse lymph; It is 0.13 that Pep1 ties lymphocytic SI to healthy C57Black/B6 mouse lymph, and it is 1.04 that Pep1 ties lymphocytic SI to H37Rv infection C57Black/B6 mouse lymph; It is 0.73 that Pep2 ties lymphocytic SI to healthy C57Black/B6 mouse lymph, and it is 1.34 (Fig. 1) that Pep2 ties lymphocytic SI to H37RvH37Rv infection C57Black/B6 mouse lymph.Explain that Pep1 and Pep2 can differential stimulus H37Rv infecting mouse spleen lymphocyte and lymph node lymphocytes, two groups of polypeptide stimulated cells are significantly bred.
Wherein, to be solvent be PBS (TAKARA company, article No.: T900 to the solvent of Pep1 solution and Pep2 solution.)
Each handles the 450nm mean light absorbency in multiple hole table 1.
Annotate: data are that 5 healthy C57Black/B6 mouse and 5 H37Rv infect the MV of three repeated experiments of C57Black/B6 mouse in the table.
Wherein, to be the contriver integrate the liquid phase mass spectrometric hyphenated technique with existing Rotofor technology for Pep1 and Pep2, the antigen of mycobacterium tuberculosis polypeptide that screens in the pulmonary tuberculosis infection focus tissue.
Claims (9)
1. a peptide species, its aminoacid sequence is shown in sequence in the sequence table 2.
2. the encoding sox of the said polypeptide of claim 1.
3. the expression cassette, recombinant vectors, transgenic cell line or the reorganization bacterium that contain the said encoding sox of claim 2.
4. the application of the described polypeptide of claim 1 in the agent of preparation lymphopoiesis.
5. the application of the described encoding sox of claim 2 in the agent of preparation lymphopoiesis.
6. according to claim 4 or 5 described application, it is characterized in that: said lymphocyte is by the mouse spleen lymphocyte of H37Rv m tuberculosis infection.
7. described polypeptide of claim 1 or the described encoding sox of claim 2 application in preparation tuberculosis disease vaccine.
8. tuberculosis disease vaccine, its activeconstituents is that the described polypeptide of claim 1 is or/and the described encoding sox of claim 2.
9. lymphopoiesis agent, its activeconstituents are that the described polypeptide of claim 1 is or/and the described encoding sox of claim 2.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012101148613A CN102675425B (en) | 2011-04-22 | 2012-04-18 | Functional mycobacterium tuberculosis antigen polypeptide and application thereof |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110101651 | 2011-04-22 | ||
| CN201110101651.6 | 2011-04-22 | ||
| CN2012101148613A CN102675425B (en) | 2011-04-22 | 2012-04-18 | Functional mycobacterium tuberculosis antigen polypeptide and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102675425A true CN102675425A (en) | 2012-09-19 |
| CN102675425B CN102675425B (en) | 2013-12-04 |
Family
ID=46729299
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012101148613A Expired - Fee Related CN102675425B (en) | 2011-04-22 | 2012-04-18 | Functional mycobacterium tuberculosis antigen polypeptide and application thereof |
| CN2012101150863A Expired - Fee Related CN102653554B (en) | 2011-04-22 | 2012-04-18 | Functional mycobacterium tuberculosis antigen polypeptide and application thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012101150863A Expired - Fee Related CN102653554B (en) | 2011-04-22 | 2012-04-18 | Functional mycobacterium tuberculosis antigen polypeptide and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN102675425B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103304636B (en) * | 2012-03-09 | 2014-12-10 | 中国医学科学院病原生物学研究所 | Mycobacterium tuberculosis candidate antigen polypeptide and application thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1694725A (en) * | 2001-08-02 | 2005-11-09 | 纽约大学 | Use of peptides for early detection of mycobacterial disease |
| CN100415771C (en) * | 2006-06-06 | 2008-09-03 | 中国人民解放军第二军医大学 | Antigen epitope for stimulating human body's protective immune response against Mycobacterium tuberculosis and use thereof |
| CN101365714A (en) * | 2005-07-01 | 2009-02-11 | 福赛特儿童口腔医院 | Tuberculosis antigen detection assays and vaccines |
| CN101555630A (en) * | 2009-03-30 | 2009-10-14 | 吉林农业大学 | Phage random peptide library of mycobacterium tuberculosis |
| CN101311189B (en) * | 2006-06-06 | 2010-09-08 | 中国人民解放军第二军医大学 | Antigen epitope for stimulating human body's protective immune response against Mycobacterium tuberculosis and use thereof |
| CN101298471B (en) * | 2006-06-06 | 2011-01-19 | 中国人民解放军第二军医大学 | Antigen epitope for stimulating human body's protective immune response against Mycobacterium tuberculosis and use thereof |
| CN102004155A (en) * | 2010-02-12 | 2011-04-06 | 复旦大学附属华山医院 | Kit and method for detecting mycobacterium tuberculosis infection and application |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101367867B (en) * | 2007-08-14 | 2011-05-25 | 深圳市达科为生物技术有限公司 | Polypeptide for specificity detection of tubercle bacillus infection contamination and reagent kit thereof |
| CN101289496B (en) * | 2008-05-30 | 2011-06-29 | 中国医学科学院医学生物学研究所 | Antigen epitope screening method capable of stimulating the body's protective immune response against Mycobacterium tuberculosis and its use |
| CN101446585B (en) * | 2008-12-29 | 2012-06-06 | 中山大学 | Reagent for detecting tubercle bacillus infection in vitro and method thereof |
-
2012
- 2012-04-18 CN CN2012101148613A patent/CN102675425B/en not_active Expired - Fee Related
- 2012-04-18 CN CN2012101150863A patent/CN102653554B/en not_active Expired - Fee Related
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1694725A (en) * | 2001-08-02 | 2005-11-09 | 纽约大学 | Use of peptides for early detection of mycobacterial disease |
| CN101365714A (en) * | 2005-07-01 | 2009-02-11 | 福赛特儿童口腔医院 | Tuberculosis antigen detection assays and vaccines |
| CN100415771C (en) * | 2006-06-06 | 2008-09-03 | 中国人民解放军第二军医大学 | Antigen epitope for stimulating human body's protective immune response against Mycobacterium tuberculosis and use thereof |
| CN101311189B (en) * | 2006-06-06 | 2010-09-08 | 中国人民解放军第二军医大学 | Antigen epitope for stimulating human body's protective immune response against Mycobacterium tuberculosis and use thereof |
| CN101298471B (en) * | 2006-06-06 | 2011-01-19 | 中国人民解放军第二军医大学 | Antigen epitope for stimulating human body's protective immune response against Mycobacterium tuberculosis and use thereof |
| CN101555630A (en) * | 2009-03-30 | 2009-10-14 | 吉林农业大学 | Phage random peptide library of mycobacterium tuberculosis |
| CN102004155A (en) * | 2010-02-12 | 2011-04-06 | 复旦大学附属华山医院 | Kit and method for detecting mycobacterium tuberculosis infection and application |
Non-Patent Citations (2)
| Title |
|---|
| 娄加陶 等: "重组结核分枝杆菌多表位肽的免疫原性研究", 《临床军医杂志》, vol. 35, no. 2, 30 April 2007 (2007-04-30), pages 162 - 164 * |
| 孙文霞 等: "结核分支杆菌抗原模拟肽的筛选和鉴定", 《中华微生物学和免疫学杂志》, vol. 32, no. 1, 31 January 2012 (2012-01-31), pages 16 - 20 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102653554B (en) | 2013-12-04 |
| CN102675425B (en) | 2013-12-04 |
| CN102653554A (en) | 2012-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wikel et al. | Tick-induced modulation of the host immune response | |
| Mestecky et al. | Mucosal immunology | |
| CN105198988B (en) | Anti-vibrio brilliant yolk antibody and preparation method thereof | |
| Mitchell et al. | Transmissible agents from human sarcoid and Crohn's disease tissues | |
| JPH06501479A (en) | antigen carrier | |
| CN1665528B (en) | Adjuvant viral particle | |
| CN106497890B (en) | A kind of XF-1 plants of porcine pseudorabies virus variant and preparation method and application | |
| Ogra | Mucosal immunity: Some historical perspective on host‐pathogen interactions and implications for mucosal vaccines | |
| WO1999027948A2 (en) | Use of soluble recombinant human cd40l protein for inhibiting in vivo immune response | |
| CN105886429A (en) | AHFGDS (aeromonas hydrophila five-gene deletion strain) attenuated bacteria without antibiotic markers and application | |
| CN102675425A (en) | Functional mycobacterium tuberculosis antigen polypeptide and application thereof | |
| Leong | Molecular and biotechnological approaches to fish vaccines | |
| Spittle | A simple and effective treatment for AIDS related Kaposi's sarcoma | |
| CN106317216B (en) | An active peptide for promoting the immune effect of H9N2 avian influenza vaccine and its application | |
| Rao | Immunology: a textbook | |
| Davis | Cellular and molecular immunology | |
| Ling et al. | A new approach to controlling ichthyophthiriasis in a closed culture system of freshwater ornamental fish. | |
| CN103509732B (en) | Edwardsiella tarda natural low virulent strain and application thereof | |
| CN102018964A (en) | Three-plasmid co-immune vaccine system capable of breaking immune tolerance and preparation method thereof | |
| Perera | At the Edge of Mysteries: The Discovery of the Immune System | |
| Fryer | Development of bacterins and vaccines for control of infectious diseases in fish | |
| CN106511993B (en) | A kind of porcine pseudorabies virus and porcine circovirus 2 type bigeminy vaccine and application | |
| Luoto et al. | Q Fever Studies in Southern California: XII. Aureomycin treatment of dairy cattle naturally infected with Coxiella burnetii | |
| CN101698100B (en) | Listeriosis vaccine and preparation method | |
| De Gee | Host parasite relationships in Trypanosoma (Duttonella) vivax with special reference to the influence of antigenic variation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20131204 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |